Changes in NRS score for pain
Pain
Results for the primary efficacy endpoint (Fig. Pain (including tingling) assessed by numeric rating scale score over 12 weeks of mirogabalin treatment: in the total (full analysis set) (The trend in reduction in NRS score from baseline was not clinically meaningful different irrespective to presence or absence of dose reduction, suspension, or discontinuation of chemotherapy due to all causes. The change in NRS score from baseline to week 12 was − 1.4 [− 2.3 to − 0.6]; Similar results were obtained using PPS data (mean change [95% CI], − 1.5 [− 2.2 to − 0.8]; 